IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Stifel Financial Corp

Stifel Financial Corp reduced its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 6.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,536 shares of the company’s stock after selling 1,888 shares during the period. Stifel Financial Corp’s holdings in IDEAYA Biosciences were worth $872,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IDYA. FMR LLC raised its holdings in shares of IDEAYA Biosciences by 12.1% in the third quarter. FMR LLC now owns 12,635,653 shares of the company’s stock worth $400,297,000 after buying an additional 1,365,570 shares during the last quarter. RA Capital Management L.P. acquired a new position in shares of IDEAYA Biosciences in the 3rd quarter valued at $42,681,000. Janus Henderson Group PLC increased its position in shares of IDEAYA Biosciences by 26.7% in the 3rd quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company’s stock valued at $163,518,000 after acquiring an additional 1,086,356 shares during the period. Jennison Associates LLC raised its stake in IDEAYA Biosciences by 136.6% in the 3rd quarter. Jennison Associates LLC now owns 972,266 shares of the company’s stock worth $30,801,000 after acquiring an additional 561,404 shares during the last quarter. Finally, Sofinnova Investments Inc. lifted its position in IDEAYA Biosciences by 47.3% during the 2nd quarter. Sofinnova Investments Inc. now owns 1,151,528 shares of the company’s stock worth $40,430,000 after acquiring an additional 369,932 shares during the period. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Stock Performance

Shares of IDYA stock opened at $25.30 on Wednesday. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of -10.86 and a beta of 0.79. IDEAYA Biosciences, Inc. has a 1 year low of $24.48 and a 1 year high of $47.74. The stock’s 50-day moving average is $28.17 and its two-hundred day moving average is $33.84.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same quarter last year, the company posted ($0.46) EPS. As a group, research analysts predict that IDEAYA Biosciences, Inc. will post -2.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on IDYA. Oppenheimer restated an “outperform” rating and issued a $53.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Royal Bank of Canada reissued an “outperform” rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, September 24th. Leerink Partners downgraded shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $41.00 to $27.00 in a report on Tuesday, November 5th. Leerink Partnrs lowered shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Finally, Citigroup decreased their target price on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating for the company in a research report on Tuesday, August 27th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $53.67.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.